Status:
UNKNOWN
Efficacy of Intrabronchial Voriconazole Instillation for Inoperable Pulmonary Aspergilloma
Lead Sponsor:
All India Institute of Medical Sciences
Conditions:
Aspergilloma
Eligibility:
All Genders
18+ years
Phase:
PHASE2
PHASE3
Brief Summary
Pulmonary aspergillomas are a common cause of recurrent hemoptysis which may be moderate to severe in 2 to 50 % of cases and may be life threatening. Surgical resection, though curative, may not be fe...
Detailed Description
Primary Objective : To compare the percentage of patients achieving reduction in hemoptysis in intrabronchial voriconazole with standard medical therapy group vs standard medical therapy alone for ino...
Eligibility Criteria
Inclusion
- Patients with mild to moderate hemoptysis AND inoperable aspergilloma/ those unwilling for surgery.
- Who have no contra-indication of flexible fibre-optic bronchoscopy
- Age \> 18 yrs AND
- Given the written informed consent to participate in the study.
Exclusion
- Patient who are not fit for FOB (e.g. hemodynamic instability)
- Patient who have life threatening hemoptysis requiring immediate bronchial artery embolization
- Patients who have underwent BAE in last 3 months
- Pregnant woman
Key Trial Info
Start Date :
December 1 2016
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 30 2019
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT03799809
Start Date
December 1 2016
End Date
January 30 2019
Last Update
January 10 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
All India Institute of Medical Sciences
New Delhi, National Capital Territory of Delhi, India, 110029